Background: O6-methylguanine-methyltransferase (MGMT) is a key enzyme for the DNA repair machinery strongly associated with response to alkylating agents in different tumors. Data on its expression and related clinical impact in neuroendocrine tumors are limited to the gastro-entero-pancreatic system, with controversial results in terms of prognostic or predictive value. In lung carcinoids, although clinical efficacy of alkylating agents has been shown in small studies, very few data to date are available on MGMT status. Objective: To assess MGMT status in lung carcinoids using multiple assays and to compare data with major clinical and pathological features. Methods: A retrospective series of 95 lung carcinoids and 51 control cases of high-grade neuroendocrine lung carcinomas was analyzed for MGMT promoter methylation, MGMT gene expression, and MGMT protein expression using pyrosequencing, quantitative real-time PCR, and immunohistochemistry, respectively. Results: MGMT protein expression was inversely correlated with MGMT promoter methylation and positively with MGMT gene expression. MGMT promoter methylation progressively increased from carcinoids to high-grade carcinomas. In the carcinoid group, decreased MGMT gene expression was significantly associated with aggressive features (atypical histotype, grade G2, larger tumor size, higher T stage, and positive nodal status) but not with survival. MGMT promoter methylation was associated with lower stage and negative nodal status. Conclusions: Our study investigated MGMT status in a large series of lung carcinoids in the attempt to move forward a rational use of alkylating agents in these tumors. Interestingly, low MGMT gene expression defines a subgroup of lung carcinoids with aggressive features.

1.
Travis
WD
,
Brambilla
E
,
Burke
AP
,
Marx
A
,
Nicholson
AG
, editors
.
WHO Classification of Tumours of the Lung, Pleura, Thymus and Heart
. 4th ed.
Lyon
:
IARC Press
;
2015
.
2.
Melosky
B
.
Advanced typical and atypical carcinoid tumours of the lung: management recommendations
.
Curr Oncol
.
2018
Jun
;
25
Suppl 1
:
S86
93
.
[PubMed]
1198-0052
3.
Papaxoinis
G
,
McCallum
L
,
Nasralla
M
,
Nonaka
D
,
Mansoor
W
.
Efficacy of the combination of capecitabine and temozolomide in patients with advanced pulmonary carcinoid tumours
.
[abstract 1499]
.
Neuroendocrinology
.
2016
;
103
:
71
.0028-3835
4.
Fazio
N
,
Ungaro
A
,
Spada
F
,
Cella
CA
,
Pisa
E
,
Barberis
M
, et al.
The role of multimodal treatment in patients with advanced lung neuroendocrine tumors
.
J Thorac Dis
.
2017
Nov
;
9
(
S15
Suppl 15
):
S1501
10
.
[PubMed]
2072-1439
5.
Crona
J
,
Fanola
I
,
Lindholm
DP
,
Antonodimitrakis
P
,
Öberg
K
,
Eriksson
B
, et al.
Effect of temozolomide in patients with metastatic bronchial carcinoids
.
Neuroendocrinology
.
2013
;
98
(
2
):
151
5
.
[PubMed]
0028-3835
6.
Christmann
M
,
Verbeek
B
,
Roos
WP
,
Kaina
B
.
O(6)-Methylguanine-DNA methyltransferase (MGMT) in normal tissues and tumors: enzyme activity, promoter methylation and immunohistochemistry
.
Biochim Biophys Acta
.
2011
Dec
;
1816
(
2
):
179
90
.
[PubMed]
0006-3002
7.
Pandith
AA
,
Qasim
I
,
Zahoor
W
,
Shah
P
,
Bhat
AR
,
Sanadhya
D
, et al.
Concordant association validates MGMT methylation and protein expression as favorable prognostic factors in glioma patients on alkylating chemotherapy (Temozolomide)
.
Sci Rep
.
2018
Apr
;
8
(
1
):
6704
.
[PubMed]
2045-2322
8.
Schraml
P
,
von Teichman
A
,
Mihic-Probst
D
,
Simcock
M
,
Ochsenbein
A
,
Dummer
R
, et al.
Predictive value of the MGMT promoter methylation status in metastatic melanoma patients receiving first-line temozolomide plus bevacizumab in the trial SAKK 50/07
.
Oncol Rep
.
2012
Aug
;
28
(
2
):
654
8
.
[PubMed]
1021-335X
9.
House
MG
,
Herman
JG
,
Guo
MZ
,
Hooker
CM
,
Schulick
RD
,
Lillemoe
KD
, et al.
Aberrant hypermethylation of tumor suppressor genes in pancreatic endocrine neoplasms
.
Ann Surg
.
2003
Sep
;
238
(
3
):
423
31
.
[PubMed]
0003-4932
10.
Owen
DH
,
Alexander
AJ
,
Konda
B
,
Wei
L
,
Hemminger
JA
,
Schmidt
CR
, et al.
Combination therapy with capecitabine and temozolomide in patients with low and high grade neuroendocrine tumors, with an exploratory analysis of O6-methylguanine DNA methyltransferase as a biomarker for response
.
Oncotarget
.
2017
Oct
;
8
(
61
):
104046
56
.
[PubMed]
1949-2553
11.
Campana
D
,
Walter
T
,
Pusceddu
S
,
Gelsomino
F
,
Graillot
E
,
Prinzi
N
, et al.
Correlation between MGMT promoter methylation and response to temozolomide-based therapy in neuroendocrine neoplasms: an observational retrospective multicenter study
.
Endocrine
.
2018
Jun
;
60
(
3
):
490
8
.
[PubMed]
1355-008X
12.
Raj
N
,
Klimstra
DS
,
Horvat
N
,
Zhang
L
,
Chou
JF
,
Capanu
M
, et al.
O6-Methylguanine DNA Methyltransferase Status Does Not Predict Response or Resistance to Alkylating Agents in Well-Differentiated Pancreatic Neuroendocrine Tumors
.
Pancreas
.
2017
Jul
;
46
(
6
):
758
63
.
[PubMed]
0885-3177
13.
Krug
S
,
Boch
M
,
Rexin
P
,
Gress
TM
,
Michl
P
,
Rinke
A
.
Impact of Therapy Sequence with Alkylating Agents and MGMT Status in Patients with Advanced Neuroendocrine Tumors
.
Anticancer Res
.
2017
May
;
37
(
5
):
2491
500
.
[PubMed]
0250-7005
14.
Girot
P
,
Dumars
C
,
Mosnier
JF
,
Muzellec
L
,
Senellart
H
,
Foubert
F
, et al.
Short article: evaluation of O6-methylguanine-DNA methyltransferase as a predicting factor of response to temozolomide-based chemotherapy in well-differentiated metastatic pancreatic neuroendocrine tumors
.
Eur J Gastroenterol Hepatol
.
2017
Jul
;
29
(
7
):
826
30
.
[PubMed]
0954-691X
15.
Walter
T
,
van Brakel
B
,
Vercherat
C
,
Hervieu
V
,
Forestier
J
,
Chayvialle
JA
, et al.
O6-Methylguanine-DNA methyltransferase status in neuroendocrine tumours: prognostic relevance and association with response to alkylating agents
.
Br J Cancer
.
2015
Feb
;
112
(
3
):
523
31
.
[PubMed]
0007-0920
16.
Schmitt
AM
,
Pavel
M
,
Rudolph
T
,
Dawson
H
,
Blank
A
,
Komminoth
P
, et al.
Prognostic and predictive roles of MGMT protein expression and promoter methylation in sporadic pancreatic neuroendocrine neoplasms
.
Neuroendocrinology
.
2014
;
100
(
1
):
35
44
.
[PubMed]
0028-3835
17.
Kulke
MH
,
Hornick
JL
,
Frauenhoffer
C
,
Hooshmand
S
,
Ryan
DP
,
Enzinger
PC
, et al.
O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors
.
Clin Cancer Res
.
2009
Jan
;
15
(
1
):
338
45
.
[PubMed]
1078-0432
18.
Lei
L
,
Jiang
Z
,
Zhang
G
,
Cheng
Q
,
Lu
H
.
MGMT promoter methylation and 1p/19q co-deletion of surgically resected pulmonary carcinoid and large-cell neuroendocrine carcinoma
.
World J Surg Oncol
.
2018
Jun
;
16
(
1
):
110
.
[PubMed]
1477-7819
19.
Pietanza
MC
,
Waqar
SN
,
Krug
LM
,
Dowlati
A
,
Hann
CL
,
Chiappori
A
, et al.
Randomized, Double-Blind, Phase II Study of Temozolomide in Combination With Either Veliparib or Placebo in Patients With Relapsed-Sensitive or Refractory Small-Cell Lung Cancer
.
J Clin Oncol
.
2018
Aug
;
36
(
23
):
2386
94
.
[PubMed]
0732-183X
20.
Rindi
G
,
Klersy
C
,
Inzani
F
,
Fellegara
G
,
Ampollini
L
,
Ardizzoni
A
, et al.
Grading the neuroendocrine tumors of the lung: an evidence-based proposal
.
Endocr Relat Cancer
.
2013
Dec
;
21
(
1
):
1
16
.
[PubMed]
1351-0088
21.
Righi
L
,
Cuccurullo
A
,
Vatrano
S
,
Cappia
S
,
Giachino
D
,
De Giuli
P
, et al.
Detection and characterization of classical and “uncommon” exon 19 Epidermal Growth Factor Receptor mutations in lung cancer by pyrosequencing
.
BMC Cancer
.
2013
Mar
;
13
(
1
):
114
.
[PubMed]
1471-2407
22.
Caplin
ME
,
Baudin
E
,
Ferolla
P
,
Filosso
P
,
Garcia-Yuste
M
,
Lim
E
, et al.;
ENETS consensus conference participants
.
Pulmonary neuroendocrine (carcinoid) tumors: european Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids
.
Ann Oncol
.
2015
Aug
;
26
(
8
):
1604
20
.
[PubMed]
0923-7534
23.
Hsu
CY
,
Ho
HL
,
Lin
SC
,
Chen
MH
,
Hsu
SP
,
Yen
YS
, et al.
Comparative Assessment of 4 Methods to Analyze MGMT Status in a Series of 121 Glioblastoma Patients
.
Appl Immunohistochem Mol Morphol
.
2017
Aug
;
25
(
7
):
497
504
.
[PubMed]
1541-2016
24.
Uno
M
,
Oba-Shinjo
SM
,
Camargo
AA
,
Moura
RP
,
Aguiar
PH
,
Cabrera
HN
, et al.
Correlation of MGMT promoter methylation status with gene and protein expression levels in glioblastoma
.
Clinics (São Paulo)
.
2011
;
66
(
10
):
1747
55
.
[PubMed]
1807-5932
25.
Cros
J
,
Hentic
O
,
Rebours
V
,
Zappa
M
,
Gille
N
,
Theou-Anton
N
, et al.
MGMT expression predicts response to temozolomide in pancreatic neuroendocrine tumors
.
Endocr Relat Cancer
.
2016
Aug
;
23
(
8
):
625
33
.
[PubMed]
1351-0088
26.
Kreth
S
,
Thon
N
,
Eigenbrod
S
,
Lutz
J
,
Ledderose
C
,
Egensperger
R
, et al.
O-methylguanine-DNA methyltransferase (MGMT) mRNA expression predicts outcome in malignant glioma independent of MGMT promoter methylation
.
PLoS One
.
2011
Feb
;
6
(
2
):
e17156
.
[PubMed]
1932-6203
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.